Problems with sleep and cognitive impairment are common among people with multiple sclerosis (MS). The present study examined the relationship between self-reported sleep and both objective and perceived cognitive impairment in MS. Data were obtained from the baseline assessment of a multi-centre intervention trial (NCT00841321). Participants were 121 individuals with MS. Nearly half (49%) of participants met the criteria for objective cognitive impairment; however, cognitively impaired and unimpaired participants did not differ on any self-reported sleep measures. Nearly two-thirds (65%) of participants met the criteria for 'poor' sleep, and poorer sleep was significantly associated with greater levels of perceived cognitive impairment. Moreover, the relationships between self-reported sleep and perceived cognitive impairment were significant beyond the influence of clinical and demographic factors known to influence sleep and cognitive functioning (e.g. age, sex, education level, disability severity, type of MS, disease duration, depression and fatigue). However, self-reported sleep was not associated with any measures of objective cognitive impairment. Among different types of perceived cognitive impairment, poor self-reported sleep was most commonly related to worse perceived executive function (e.g. planning/organization) and prospective memory. Results from the present study emphasize that self-reported sleep is significantly and independently related to perceived cognitive impairment in MS. In terms of clinical implications, interventions focused on improving sleep may help improve perceived cognitive function and quality of life in this population; however, the impact of improved sleep on objective cognitive function requires further investigation.
impairment (Spira et al., 2014; Stavitsky et al., 2012; Szelenberger and Niemcewicz, 2000) ; however, similar associations have not been sufficiently explored in people with MS. Given that cognitive impairment affects 40-60% of individuals with MS (Archibald and Fisk, 2000; Chiaravalloti and Deluca, 2008; Rao et al., 1991) , additional research on the impact of sleep has important clinical and functional implications for this patient population.
Sater and colleagues were among the first to explicitly examine the relationship between sleep and cognitive impairment in MS (Sater et al., 2015) . The study demonstrated that sleep efficiency (i.e. percentage of time in bed spent asleep) positively correlated with performance on objective measures of executive function and information processing speed. Another recent study examined polysomnographic (PSG) indicators of sleep apnea, and found associations with measures of verbal memory, visual memory and executive function (Braley et al., 2016) . However, the former study did not incorporate self-reported measures of sleep and cognitive impairment, and the latter study focused predominately on sleep-related breathing disturbances, which represent only one aetiology of sleep problems in MS.
Given the significant financial and physical challenges of objective sleep measurement (e.g. overnight PSG study), self-report is typically the first line of assessment for sleep disturbance in MS clinical settings and represents an important starting point for intervention. Self-report measures provide a patient-centred approach to studying sleep in MS (Bamer et al., 2010; Fogelberg et al., 2015; Lauderdale et al., 2008) . For example, the Pittsburgh Sleep Quality Index (PSQI) is a self-report measure that provides a total score to assess general sleep, seven component scores to assess specific aspects of sleep, and a suggested cut-score of 5 to differentiate 'good' versus 'poor' sleepers (Buysse et al., 1989) . A recent study in people with MS found that 'poor' sleepers reported lower physical and mental healthrelated quality of life than 'good' sleepers (Merlino et al., 2009) .
Measures of cognitive impairment have demonstrated inconsistencies between objective and self-report measures (Benedict et al., 2004; Carone et al., 2005; Kinsinger et al., 2010; Lovera et al., 2006 Lovera et al., , 2012 . Given these findings, it is reasonable to expect that self-reported sleep may be more strongly related to perceived than objective cognitive impairment; however, these differences remain to be empirically tested. Furthermore, these relationships have not been examined with regard to specific domains of perceived cognitive impairment (e.g. attention, memory, executive function), which may differ in their associations with sleep.
The present study featured two primary aims and one exploratory aim. First, we compared 'cognitively impaired' (CI) with 'cognitively unimpaired' (CU) participants on selfreport measures of sleep, controlling for the influence of potentially confounding demographic and clinical variables (Aim 1). We predicted that CI participants would report poorer sleep relative to CU participants, both on the total PSQI and on the PSQI component scores. Second, we examined selfreported sleep on the total PSQI and its associations with perceived and objective measures of cognitive impairment (Aim 2). We predicted that self-reported sleep would be related to both perceived and objective cognitive impairment, but that perceived cognitive impairment would yield stronger associations. Finally, we explored individual PSQI components and their associations with specific domains of cognitive impairment (Exploratory Aim).
MAT ERIALS AN D METH ODS

Participants and procedures
This study was conducted at two VA Medical Centers. The Institutional Review Boards of both sites approved all study procedures, and all participants provided written informed consent. Participants were recruited in the context of a previously reported clinical trial investigating the effects of Ginkgo biloba for cognitive impairment in MS (Lovera et al., 2012) . Data were collected from 121 participants at baseline, prior to treatment randomization. As indicated in prior publications (Cameron et al., 2014; Hughes et al., 2015) , participants were recruited from the two VA clinics, and their affiliated institutions and communities. Inclusion criteria included: a physician-confirmed diagnosis of MS, disease stability for at least 30 days, and a score of at least 1 SD below the normative sample mean on at least one objective cognitive test. For the purposes of this study, participants were classified as 'CI' using a more stringent and clinically relevant definition of cognitive impairment: 1.5 SD below the normative sample mean on two cognitive tests; and/or 2 SDs below the normative sample mean on one measure of objective cognitive impairment. Participants who did not meet these criteria were classified as 'CU'. These classifications allowed us compare sleep between CI and CU participants. Participants were excluded if they demonstrated: severe depressive symptomatology [≥29 on the Beck Depression Inventory-II (BDI-II); Beck et al., 1996] ; colour-blindness; poor visual acuity; or use of anticoagulant medications, which were contraindicated for Ginkgo biloba (Diamond et al., 2000) .
Measures
Sleep
Participants completed the PSQI, a nine-item scale that assesses self-reported sleep during the past month (Buysse et al., 1989 (Buysse et al., 1989) . A greater cutscore of 7 has been used in studies with other medical populations (e.g. breast cancer, chronic pain). For the present study, we calculated descriptive statistics for both cut-scores. In order to maintain consistency with a previous MS study (Merlino et al., 2009) and with the wider sleep literature, a cut-score of 5 was used for inferential statistics.
Cognitive impairment
Participants completed four tests of objective cognitive impairment and one measure of perceived cognitive impairment. Objective measures included: the Delayed Free Recall trial of the California Verbal Learning Test-II (CVLT-II), a measure of verbal memory (Delis et al., 2000) ; the Color-Word trial of the Victoria Stroop Color-Word Test (VSCWT), a measure of attention, processing speed and inhibitory control (Strauss et al., 2006) ; the 2-s Paced Auditory Serial Addition Test (PASAT), a test of auditory working memory, attention and processing speed (Gronwall, 1977) ; and the Controlled Oral Word Association Test (COWAT), a speeded test of phonemic fluency (Benton et al., 1983) . For each test, Z-scores (M = 0, SD = 1.0) were calculated based on an age-and gendermatched normative sample, with higher scores indicating better performance. Perceived cognitive impairment was evaluated using the Perceived Deficits Questionnaire (PDQ), a 20-item selfreport scale that assesses how often participants experienced cognitive problems during the past 4 weeks (Marrie et al., 2003) . This measure has been validated in MS and demonstrates excellent internal consistency (Cronbach's a = 0.92). Scores range from 0 to 80, with higher scores indicating greater levels of perceived cognitive impairment. The PDQ includes four subscale scores, each ranging from 0 to 20, assessing the following domains: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization.
Demographic variables
Basic demographics were collected from participants at baseline to be considered for inclusion as covariates in the present study. Variables included: age (in years); sex (0 = 'female', 1 = 'male'); and education level (0 = 'less than college degree', 1 = 'college degree or higher').
Clinical variables
Clinical variables were assessed and considered for inclusions as covariates, including:
disease duration (in years); disability severity; depressive symptomatology; and fatigue severity. Disability severity was determined by the Expanded Disability Status Scale (EDSS), a quantitative measure of disability that ranges from 0 to 10, with higher scores indicating more severe disability (Kurtzke, 1983) . Depressive symptomatology was assessed using the BDI-II, a 21-item self-report scale that corresponds to diagnostic criteria for depression (Beck et al., 1996) . For the present study, one item ('Changes in Sleeping Pattern') was omitted to reduce potential multicollinearity with the PSQI. Total BDI-II scores reflected the sum of the remaining 20 items. Given the study's exclusion criteria, the possible range of scores on this measure was 0-28, and internal consistency was good (Cronbach's a = 0.86). Fatigue severity was assessed using the Fatigue Severity Scale (FSS), a nine-item scale that assesses interference in daily activities due to fatigue (Krupp et al., 1989) . Scores range from 9 to 63, with higher scores indicating worse fatigue. The FSS demonstrated excellent internal consistency (Cronbach's a = 0.91).
Statistical analyses
Analyses were performed using IBM SPSS calculated to determine the magnitude of group differences. For Aim 2, preliminary zero-order correlations were calculated between potential covariates (i.e. demographic variables and clinical variables) and the study's primary variables of interest (i.e. total PSQI and measures of cognitive impairment). Any demographic or clinical variable that correlated at least weakly with sleep and/or one of the cognitive impairment variables (r > 0.10) was included as a covariate in subsequent analyses. Next, a series of hierarchical regressions assessed the relationship between total PSQI and each of the five cognitive impairment variables (i.e. PDQ, CVLT-II, VSCWT, PASAT and COWAT). Covariates were entered into the first step, and total PSQI was entered into the second step.
For our Exploratory Aim, a series of multivariate regression analyses examined the relationships between individual PSQI components and each domain of the PDQ, controlling ª 2017 European Sleep Research Society for relevant covariates. For each analysis, one of the seven PSQI components was entered as the independent variable, and the four PDQ subscales were entered together as dependent variables.
RESUL TS Sample characteristics
The sample ranged in age from 24 to 65 years (M = 52.1, SD = 9.1), was 54.5% female (n = 66) and was highly educated, with 54 (44.6%) participants having completed a college degree. Disease durations ranged from 1 to 47 years (M = 21.1, SD = 11.7), with 78 (64.5%) participants having the RRMS subtype. On the EDSS, 44 (36.4%), 38 (31.4%) and 39 (32.2%) participants demonstrated mild, moderate and severe disability levels, respectively. On average, the sample endorsed minimal depressive symptomatology (BDI-II: M = 8.8, SD = 6.3) and moderate fatigue severity (FSS: M = 49.5, SD = 11.05).
Participants' mean total PSQI score (M = 7.9, SD = 4.4; range = 1-19) was higher than the normative sample mean for healthy adults (M = 2.7, SD = 1.7, t = 13.00, P < 0.001), and was comparable to a previously published MS sample mean (M = 6.8, SD = 4.5, t = 1.92, P = 0.97). Using the recommended PSQI cut-score of 5, 79 (65.3%) participants met the criteria for 'poor' sleep. Using a more conservative cut-score of 7, 54 (44.6%) participants were still classified as 'poor' sleepers. With regard to sleep duration, 45 (37.2%) participants slept less than 7 h, the minimum number of hours recommended by the American Academy of Sleep Medicine. Additionally, 52 (43.0%) respondents reported sleep efficiency below the recommended 85%.
Using the pre-determined criteria for classifying cognitive impairment, 59 (48.8%) participants were classified as CI. Mean scores for all four objective measures of cognitive impairment fell below those of the normative sample (CVLT: M = À0.5, SD = 1.2; VSCWT: M = À1.0, SD = 1.5; PASAT: M = À1.3, SD = 0.9; COWAT: M = À0.9, SD = 1.0), with the poorest scores noted for the PASAT. Mean total PDQ scores (M = 37.8, SD = 12.5) indicated moderate levels of perceived cognitive impairment. Among the four PDQ subscales, levels of perceived impairment were greatest for the Attention/Concentration subscale (Attention/Concentration: M = 10.2, SD = 3.5; Retrospective Memory: M = 9.9, SD = 3.8; Prospective Memory: M = 7.8, SD = 3.1; Planning/Organization: M = 9.8, SD = 3.9).
Comparisons between CI and CU participants
Preliminary t-tests and chi-square tests were performed between CI and CU participants on demographic and clinical variables. Groups did not differ with regard to age, sex, education level, MS subtype, disease duration, EDSS, BDI-II or FSS (all P > 0.05). A one-way ANCOVA revealed no significant group differences between CI and CU participants on the total PSQI (F 1,108 = 3.31, P = 0.07, g 2 = 0.03). An omnibus MANCOVA revealed no significant group differences between CI and CU participants on the seven PSQI component scores (F 7,102 = 1.05, P = 0.40, g 2 = 0.07). Given the non-significant omnibus test, post hoc analyses were not performed for individual PSQI component scores.
Correlational analyses
Correlations between potential covariates (i.e. demographic variables and clinical variables) and the study's primary variables of interest (i.e. total PSQI and cognitive impairment measures) are presented in Table 1 . Age, sex, education level, disease duration, MS subtype and disability severity were weaklycorrelated (0.10 < r < 0.30) with at least onemeasure of sleep and/or cognitive impairment; however, even with the use of a liberal significance threshold (P < 0.10) several of these associations were non-significant. Additionally, depression and fatigue were moderately correlated (0.30 < r < 0.50) with total PSQI and total PDQ (P < 0.001), and were weakly correlated with at least one of the objective cognitive impairment measures. Given these significant correlations and the potential for confounding, all demographic and clinical variables were included as covariates in subsequent analyses.
Hierarchical regression analysis
The relationship between total PSQI and perceived cognitive impairment (total PDQ) was assessed using hierarchical regression (Table 2) , controlling for demographic and clinical covariates. In the first step, demographic and clinical variables explained 33.4% of the variance in total PDQ (F 8,109 = 6.82, P < 0.001). The addition of total PSQI in the second step accounted for an additional 8.0% of the variance in total PDQ (DR 2 = 0.08, DF 1,108 = 14.78, P < 0.001). In the final model, age, FSS and total PSQI were significantly associated with total PDQ (age: t = À3.10, P = 0.002; FSS: t = 3.80, P < 0.001; PSQI: t = 3.85, P < 0.001). As shown in Table 2 , effect sizes (bs) were medium in magnitude for age, FSS and total PSQI. The final model was statistically significant and explained 41.4% of the variance in total PDQ (R 2 = 0.41, F 9,108 = 8.47, P < 0.001).
Hierarchical regressions were conducted to assess the relationships between total PSQI and each of the four objective cognitive impairment measures (i.e. CVLT-II, VSCWT, PASAT and COWAT). For the CVLT-II, demographic and clinical variables explained a significant proportion of the variance in cognitive impairment (F 8,109 = 4.12, P < 0.001); however, the addition of total PSQI did not significantly improve the model (DF 1,108 = 0.06, P = 0.80) and total PSQI was not associated with the CVLT-II (B = 0.01, t = 0.25, P = 0.80). Similar findings were observed for the other objective measures, where total PSQI was not associated with the VSCWT (B = 0.01, t = 0.12, P = 0.91), PASAT (B = 0.01, t = 0.08, P = 0.94) or COWAT (B = 0.02, t = 0.76, P = 0.45). 
Exploratory multivariate regression analysis
An exploratory series of multivariate regressions was performed to assess the relationship between the seven PSQI component scales and the four PDQ subscales, while controlling for demographic and clinical covariates (Table 3) . Each PSQI component was related to at least one of the PDQ subscales.
Six of the seven PSQI components (all except Disturbances) were significantly associated with the Planning/ Organization subscale of the PDQ (significant Bs from 0.61 to 1.37). Five of the seven PSQI components (all except Latency and Medications) were significantly associated with the Prospective Memory subscale (significant Bs from 0.74 to 1.24). The Retrospective Memory subscale was the least likely to be associated with self-reported sleep, as it was only related to two of the PSQI subscales (Medications and Daytime Dysfunction). The PSQI subscales most commonly associated with perceived cognitive impairment were Efficiency, Medications, and Daytime Dysfunction, as each was significantly associated with three of the four PDQ subscales (all P < 0.05). Effect sizes ranged from small to medium (g 2 from 0.01 to 0.07), with the largest effects sizes noted for associations between the PDQ Prospective Memory subscale and the PSQI Efficiency and Daytime Dysfunction subscales.
DISCUSSION
Results of the present study extended previous findings regarding the prevalence of sleep problems among individuals with MS, and the relationship between sleep and cognitive impairment in this population. To our knowledge, this is the first study to compare cognitively impaired versus unimpaired individuals on self-report measures of sleep, and to examine the relationships between self-reported sleep and both perceived and objective cognitive impairment in MS. Importantly, the present analyses also controlled for important demographic and clinical variables known to influence sleep and cognitive functioning in MS.
Using respective PSQI cut-scores of 5 and 7, 65 and 45% of our sample met criteria for significant sleep problems. This prevalence was generally consistent with prior studies of sleep disturbance in MS (Bamer et al., 2008; Merlino et al., 2009 ). The present sample also reported insufficient sleep duration (<7 h) and poor sleep efficiency (<85%).
Among the key findings of this study, participants with objective cognitive impairment did not differ from participants without cognitive impairment on any PSQI measures. . n = 121; *P < 0.10; † P < 0.05; ‡ P < 0.01; § P < 0.001. However, poorer self-reported sleep was significantly associated with worse perceived cognitive impairment, even after controlling for factors such as depression and fatigue, which were also significantly associated with worse perceived cognitive impairment. Results underscore that perceptions of cognitive functioning are likely a complex phenomenon influenced by sleep as well as fatigue and mood states. However, the relationship between self-reported sleep and objective cognitive functioning is less clear, as poor selfreported sleep was not related to any objective measures of cognitive impairment.
Results are consistent with previous findings of discrepancies between self-report and objective measures in both MS and sleep research literatures (Benedict et al., 2004; Lauderdale et al., 2008) . A study of self-reported sleep in older adults found that the PSQI was not effective for distinguishing people with and without objective cognitive impairment (Adam et al., 2014) . Similarly, a study of participants with MS found that perceived cognitive impairment correlated with depression and fatigue, but not with objective cognitive impairment (Middleton et al., 2006) . Thus, results suggest that self-reported sleep may be more predictive of participants' perception and internal experience of their psychological and cognitive status than of their objective cognitive performance (Kinsinger et al., 2010) .
The present study was also the first to explore how different aspects of self-reported sleep relate to specific domains of perceived cognitive impairment in MS. Prior research has relied predominately on global sleep and cognitive impairment measures (e.g. total PSQI, total PDQ). In contrast, the present study explored associations between the seven PSQI components and the four PDQ domains. The majority of PSQI components correlated with perceived problems with planning/organization and prospective memory, suggesting that multiple types of sleep problems may interfere with perceived executive function and memory for future tasks and planned behaviours. A similar finding was demonstrated in individuals with Parkinson's disease, where poor sleep quality was related to problems with executive function (Stavitsky et al., 2012) .
Additional research is needed to determine the directionality of the relationships between sleep, cognitive impairment, depression and fatigue. Previous research on depression and sleep disturbance has suggested a bi-directional relationship, where poor sleep can exacerbate depressive symptomatology, and depression can impair sleep quantity and quality (Franzen and Buysse, 2008) . Thus, interventions aimed at reducing depression and fatigue may have a positive impact on sleep as well as perceived cognitive impairment. Future research is needed to determine what interventions in each or all of these areas will best lead to clinically meaningful improvements in cognitive functioning.
With regard to study limitations, single time-point assessment precluded the examination of changes over time and the determination of whether improvements in sleep supported improvements in cognitive function. Second, assessment of sleep was restricted to self-report on the PSQI. While the PSQI is validated for use in MS and provides important information across a variety of aspects of sleep, research has cautioned the over-reliance on self-report sleep measures, highlighting discrepancies between objective and subjective measures, and the influence of depression on subjective sleep (Maglione et al., 2012) . Future research should employ self-report and objective sleep measures, cognitive impairment, depression and fatigue to fully understand the nuances of assessing these commonly co-occurring and potentially bidirectional symptoms. Future research will also benefit from the inclusion of validity and effort measures, which were not administered in the present study. Third, given the eligibility criteria of the original trial for which the present data were (Lovera et al., 2012) , present results may not generalize to the full MS population. Future studies will benefit from the inclusion of participants across the full spectrum of these measures. Finally, relevant medical record data such as sleep-related co-morbidities (e.g., restless legs syndrome, obstructive sleep apnea, etc.) and magnetic resonance imaging findings (e.g. localization of MS lesions and atrophy) were not collected from participants in the present sample; thus, information on specific aetiologies of sleep problems was not available and should be a focus of future research. Despite these limitations, results from this study showed that self-reported sleep in MS is significantly and independently related to perceived cognitive impairment, particularly impairments in planning, organization and prospective memory. Perceived cognitive impairment represents a significant problem among individuals with MS and can impact individuals' expectations for how they carry out daily work, personal and family activities (Samartzis et al., 2014) . Given the prevalence of poor sleep in this population, and its association with perceived cognitive impairment, interventions aimed at improving sleep have potential clinical implications for improving perceived cognitive function, and ultimately quality of life in MS.
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